Company: CYTK
Filing Date: 2025-09-22
Form Type: 8-K
Source: 0001193125-25-209437
Chunk: 0

Company: CYTOKINETICS INC
Filing Date: 2025-09-22
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01 Entry Into a Material Definitive Agreement.

Indenture and Notes

On September 19, 2025, Cytokinetics, Incorporated (the “ Company”) issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “ Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $100.0 million aggregate principal amount of Notes. The Notes were issued pursuant to, and are governed by, an indenture (the “ Indenture”), dated as of September 19, 2025, between the Company and U. S. Bank Trust Company, National Association, as trustee (the “ Trustee”).

The Notes are the Company’s senior, unsecured obligations and are (i) senior in right of payment to the Company’s future indebtedness that is expressly subordinated to the Notes in right of payment; (ii) equal in right of payment with all of the Company’s indebtedness that is not so subordinated, including the Company’s 4.00% Convertible Senior Notes due 2026 and its 3.50% Convertible Senior Notes due 2027 (the “2027 Notes”); (iii) effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness; and (iv) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries.

The Notes bear interest at a rate of 1.75% per year, payable semiannually in arrears on April 1 and October 1 of each year, beginning on April 1, 2026. The Notes will mature on October 1, 2031, unless earlier converted, redeemed or repurchased. The Notes are convertible into cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, at the Company’s election, based on the applicable conversion rate(s).

Noteholders may convert all or any portion of their Notes at their option only in the following circumstances: (i) during any calendar quarter (and only during such calendar quarter) commencing after the calendar quarter ending on December 31, 2025, if the last reported sale price per share of the Company’s common